Expression patterns of podocyte-associated mRNAs in patients with proliferative or non-proliferative glomerulopathies.

Autor:	Rodrigues PG; Post-Graduate Program in Medicine: Medical Sciences, Federal University of Rio Grande do Sul Porto Alegre, RS, Brazil., Bringhenti RN; Division of Pathology, Hospital de Clínicas de Porto Alegre Porto Alegre, RS, Brazil., do Nascimento JF; Post-Graduate Program in Medicine: Medical Sciences, Federal University of Rio Grande do Sul Porto Alegre, RS, Brazil., Joelsons G; Post-Graduate Program in Medicine: Medical Sciences, Federal University of Rio Grande do Sul Porto Alegre, RS, Brazil., dos Santos M; Post-Graduate Program in Medicine: Medical Sciences, Federal University of Rio Grande do Sul Porto Alegre, RS, Brazil., Pereira S; Post-Graduate Program in Medicine: Medical Sciences, Federal University of Rio Grande do Sul Porto Alegre, RS, Brazil., Veronese FV; Post-Graduate Program in Medicine: Medical Sciences, Federal University of Rio Grande do Sul Porto Alegre, RS, Brazil ; Division of Nephrology, Hospital de Clínicas de Porto Alegre Porto Alegre, RS, Brazil.
Jazyk:	angličtina
Zdroj:	International journal of clinical and experimental pathology [Int J Clin Exp Pathol] 2014 Apr 15; Vol. 7 (5), pp. 2185-98. Date of Electronic Publication: 2014 Apr 15 (Print Publication: 2014).
Abstrakt:	Aim: It is not clear how the podocyte damage manifests in different glomerulopathies. This study evaluated the podocyte-associated mRNA profiles in renal tissue and urine of patients with proliferative (PGs) or non-proliferative (NPGs) glomerulopathies. Methods: Messenger RNA levels of nephrin, podocin, podocalyxin, synaptopodin, and alpha-actinin-4 were measured in the kidney tissue and urinary cells by real-time polymerase chain reaction. Podocyte-associated mRNAs were correlated with proteinuria and renal function, and the effect of immunosuppressive treatment of PGs and NPGs on urine mRNAs was assessed up to one year of follow up. Results: Podocyte-associated mRNAs were expressed consistently less in kidney tissue from patients with NPGs, and urinary podocyte mRNA levels were significantly higher in the PG group. After six months of immunosuppressive therapy, patients with PGs showed a significant reduction in the expression of podocin, podocalyxin, and alpha-actinin-4 compared with baseline (p<0.001). In the NPG group, alpha-actinin-4 levels decreased (p=0.008), and there was also a trend toward reduced podocalyxin mRNA (p=0.08). Urine podocyte-associated mRNAs correlated with the level of proteinuria at baseline and at six months, and there was a trend toward an inverse correlation between urinary mRNAs and kidney function at one year of follow up. Conclusions: Podocyte-associated mRNAs were inhibited in kidney tissue concomitantly with their increase in urine in these patients with glomerulopathies. Different profiles of mRNA expression were seen, pointing to a higher degree of intra-renal podocytopenia in the NPGs and of podocyturia in the PGs. The immunosuppressive therapy effectively reduced the urinary levels of podocyte-associated mRNAs.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu